Core Insights - Protalix Bio Therapeutics (PLX) has announced a significant regulatory and clinical milestone for its Fabry disease treatment in Europe, indicating positive progress in its drug development efforts [1] Company Overview - Protalix Bio Therapeutics is focused on developing innovative therapies, particularly in the biotechnology sector, with an emphasis on unique mechanisms of action and first-in-class therapies [1] Market Context - The biotechnology sector is characterized by breakthrough science that can lead to substantial returns, but it also requires careful scrutiny due to inherent risks [1]